Investigating Opioid Receptor Activity through Biocatalytic Halogenation and Oxidation of Mitragynine

Read full text Summarise with VIRAT
Authors: Natalia R. Harris, Alexander J. Powell, Harrison M. Snodgrass, Sahar Amin, Sean A. Newmister, Brian J. Curtis, Danny Li, Zehra A Husaini, Linnea Verhey-Henke, Janet Lynn Smith, Filipa M. Pereira, Jared C. Lewis
+2 more John R. Traynor, David H. Sherman
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The development of safer opioid therapeutics remains an urgent challenge, given the limitations and adverse effects of current μ-opioid receptor (MOR) agonists. Natural products such as mitragynine, the predominant alkaloid from Mitragyna speciosa (kratom), provide structurally complex scaffolds for probing MOR signaling bias and structure–activity relationships. However, enzymatic strategies for mitragynine modification remain largely restricted to native plant or non-native eukaryotic enzymes, which are often insoluble, low-yielding, or incompatible with heterologous expression, limiting their use for late-stage derivatization. Here, we establish a modular biocatalytic platform that repurposes noncognate oxidative enzymes for in vivo diversification of mitragynine. Using flavin-dependent monooxygenases (CtdE) and an orphan halogenase (D3) from Saccharophagus degradans, we achieved site-selective N -oxidation and C10 bromination, respectively, and demonstrate that these reactions can be combined in a single Escherichia coli host to perform sequential halogenation and oxidation directly from the parent alkaloid. The resulting analogues, including 10-bromo-mitragynine and its N -oxide, exhibit distinct MOR binding and G protein signaling profiles while failing to recruit β-arrestin. Collectively, these findings introduce a generalizable whole-cell platform for programmable, multistep alkaloid functionalization and highlight how biocatalysis can drive pharmacology to guide the discovery of novel bioactive scaffolds.

Fields of Study & Subjects

Alkaloids: synthesis and pharmacology Enzyme Catalysis and Immobilization Plant biochemistry and biosynthesis

Publication details

Journal / source
ACS Chemical Biology
Volume
21
Issue
4
Pages
733–743
Publication date
30 March 2026
Language
EN